Abstract
Multimodal imaging agents were first introduced a decade ago and consist of a targeting moiety that is dual-labeled with radioactive and fluorescent contrast. These compounds allow whole-body and intraoperative imaging to be performed through administration of a single agent and provide complementary diagnostic information that can be used to guide tumor resection. Since their initial evaluation, interest in dual-labeled agents has continued to grow and their design has subsequently evolved alongside the development of novel chelating agents, improved fluorophores, and highly selective coupling techniques for bioconjugate formation. In this review, will discuss how changes in the labeling components and schemes for multimodal agent development have impacted imaging performance and will focus on antibody- and peptide-based agents as models for dual labeling. We will also describe the growing role of modular dual labeling strategies as well as direct labeling methods using radiohalogens.
Keywords: Dual labeling, molecular imaging, multimodality, near-infrared fluorescence, radioisotope, nuclear imaging.
Current Medicinal Chemistry
Title:Advances in the Development of Multimodal Imaging Agents for Nuclear/Near-infrared Fluorescence Imaging
Volume: 22 Issue: 29
Author(s): S.C. Ghosh and A. Azhdarinia
Affiliation:
Keywords: Dual labeling, molecular imaging, multimodality, near-infrared fluorescence, radioisotope, nuclear imaging.
Abstract: Multimodal imaging agents were first introduced a decade ago and consist of a targeting moiety that is dual-labeled with radioactive and fluorescent contrast. These compounds allow whole-body and intraoperative imaging to be performed through administration of a single agent and provide complementary diagnostic information that can be used to guide tumor resection. Since their initial evaluation, interest in dual-labeled agents has continued to grow and their design has subsequently evolved alongside the development of novel chelating agents, improved fluorophores, and highly selective coupling techniques for bioconjugate formation. In this review, will discuss how changes in the labeling components and schemes for multimodal agent development have impacted imaging performance and will focus on antibody- and peptide-based agents as models for dual labeling. We will also describe the growing role of modular dual labeling strategies as well as direct labeling methods using radiohalogens.
Export Options
About this article
Cite this article as:
Ghosh S.C. and Azhdarinia A., Advances in the Development of Multimodal Imaging Agents for Nuclear/Near-infrared Fluorescence Imaging, Current Medicinal Chemistry 2015; 22 (29) . https://dx.doi.org/10.2174/0929867322666150904111214
DOI https://dx.doi.org/10.2174/0929867322666150904111214 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Molecular Basis of Herpesviruses as Oncolytic Agents
Current Pharmaceutical Biotechnology New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design Current Concepts for the Combined Treatment Modality of Ionizing Radiation with Anticancer Agents
Current Pharmaceutical Design Brief Messages to Promote Prevention and Detection of Sexually Transmitted Infections
Current HIV Research Immunomodulatory Effect of Probiotic Bacteria
Recent Patents on Inflammation & Allergy Drug Discovery Synthesis and Biological Activity of Some New N1-(4-oxoquinolin-6-yl) amidrazones
Letters in Organic Chemistry KRAS Mutation Testing of Colorectal Cancer for Anti-EGFR Therapy: Dogmas Versus Evidence
Current Cancer Drug Targets Intestinal Microbiota: A Regulator of Intestinal Inflammation and Cardiac Ischemia?
Current Drug Targets Cytokines in Systemic Lupus Erythematosus
Current Molecular Medicine Cancer Cell Reprogramming: Stem Cell Differentiation Stage Factors and An Agent Based Model to Optimize Cancer Treatment
Current Pharmaceutical Biotechnology Subject Index Volume 6
Mini-Reviews in Medicinal Chemistry High-throughput Screening Identifies Small Molecule Inhibitors of Molecular Chaperones
Current Pharmaceutical Design Development of Peptides as Potential Drugs for Cancer Therapy
Current Pharmaceutical Design Comparative Mass Spectrometry & Nuclear Magnetic Resonance Metabolomic Approaches for Nutraceuticals Quality Control Analysis: A Brief Review
Recent Patents on Biotechnology Transcriptional Regulation of mPGES1 in Cancer: An Alternative Approach to Drug Discovery?
Current Drug Targets Atypical GTPases as Drug Targets
Anti-Cancer Agents in Medicinal Chemistry Plasma Infusions into Porcine Cerebral White Matter Induce Early Edema, Oxidative Stress, Pro-Inflammatory Cytokine Gene Expression and DNA Fragmentation: Implications for White Matter Injury with Increased Blood- Brain-Barrier Permeability
Current Neurovascular Research Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets A Novel Assay Platform for the Detection of Translation Modulators of Spermidine/ Spermine Acetyltransferase
Current Pharmaceutical Design The Traces of Sound: Taking the Road to Skin
Current Rheumatology Reviews